Cargando…

The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project

OBJECTIVES: Clinical trials are complicated, expensive, time-consuming, and frequently do not lead to discoveries that improve the health of patients with disease. Adaptive clinical trials have emerged as a methodology to provide more flexibility in design elements to better answer scientific questi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guetterman, Timothy C, Fetters, Michael D, Mawocha, Samkeliso, Legocki, Laurie J, Barsan, William G, Lewis, Roger J, Berry, Donald A, Meurer, William J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648086/
https://www.ncbi.nlm.nih.gov/pubmed/29085638
http://dx.doi.org/10.1177/2050312117736228
_version_ 1783272331904286720
author Guetterman, Timothy C
Fetters, Michael D
Mawocha, Samkeliso
Legocki, Laurie J
Barsan, William G
Lewis, Roger J
Berry, Donald A
Meurer, William J
author_facet Guetterman, Timothy C
Fetters, Michael D
Mawocha, Samkeliso
Legocki, Laurie J
Barsan, William G
Lewis, Roger J
Berry, Donald A
Meurer, William J
author_sort Guetterman, Timothy C
collection PubMed
description OBJECTIVES: Clinical trials are complicated, expensive, time-consuming, and frequently do not lead to discoveries that improve the health of patients with disease. Adaptive clinical trials have emerged as a methodology to provide more flexibility in design elements to better answer scientific questions regarding whether new treatments are efficacious. Limited observational data exist that describe the complex process of designing adaptive clinical trials. To address these issues, the Adaptive Designs Accelerating Promising Treatments Into Trials project developed six, tailored, flexible, adaptive, phase-III clinical trials for neurological emergencies, and investigators prospectively monitored and observed the processes. The objective of this work is to describe the adaptive design development process, the final design, and the current status of the adaptive trial designs that were developed. METHODS: To observe and reflect upon the trial development process, we employed a rich, mixed methods evaluation that combined quantitative data from visual analog scale to assess attitudes about adaptive trials, along with in-depth qualitative data about the development process gathered from observations. RESULTS: The Adaptive Designs Accelerating Promising Treatments Into Trials team developed six adaptive clinical trial designs. Across the six designs, 53 attitude surveys were completed at baseline and after the trial planning process completed. Compared to baseline, the participants believed significantly more strongly that the adaptive designs would be accepted by National Institutes of Health review panels and non-researcher clinicians. In addition, after the trial planning process, the participants more strongly believed that the adaptive design would meet the scientific and medical goals of the studies. CONCLUSION: Introducing the adaptive design at early conceptualization proved critical to successful adoption and implementation of that trial. Involving key stakeholders from several scientific domains early in the process appears to be associated with improved attitudes towards adaptive designs over the life cycle of clinical trial development.
format Online
Article
Text
id pubmed-5648086
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-56480862017-10-30 The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project Guetterman, Timothy C Fetters, Michael D Mawocha, Samkeliso Legocki, Laurie J Barsan, William G Lewis, Roger J Berry, Donald A Meurer, William J SAGE Open Med Original Article OBJECTIVES: Clinical trials are complicated, expensive, time-consuming, and frequently do not lead to discoveries that improve the health of patients with disease. Adaptive clinical trials have emerged as a methodology to provide more flexibility in design elements to better answer scientific questions regarding whether new treatments are efficacious. Limited observational data exist that describe the complex process of designing adaptive clinical trials. To address these issues, the Adaptive Designs Accelerating Promising Treatments Into Trials project developed six, tailored, flexible, adaptive, phase-III clinical trials for neurological emergencies, and investigators prospectively monitored and observed the processes. The objective of this work is to describe the adaptive design development process, the final design, and the current status of the adaptive trial designs that were developed. METHODS: To observe and reflect upon the trial development process, we employed a rich, mixed methods evaluation that combined quantitative data from visual analog scale to assess attitudes about adaptive trials, along with in-depth qualitative data about the development process gathered from observations. RESULTS: The Adaptive Designs Accelerating Promising Treatments Into Trials team developed six adaptive clinical trial designs. Across the six designs, 53 attitude surveys were completed at baseline and after the trial planning process completed. Compared to baseline, the participants believed significantly more strongly that the adaptive designs would be accepted by National Institutes of Health review panels and non-researcher clinicians. In addition, after the trial planning process, the participants more strongly believed that the adaptive design would meet the scientific and medical goals of the studies. CONCLUSION: Introducing the adaptive design at early conceptualization proved critical to successful adoption and implementation of that trial. Involving key stakeholders from several scientific domains early in the process appears to be associated with improved attitudes towards adaptive designs over the life cycle of clinical trial development. SAGE Publications 2017-10-16 /pmc/articles/PMC5648086/ /pubmed/29085638 http://dx.doi.org/10.1177/2050312117736228 Text en © The Author(s) 2017 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Guetterman, Timothy C
Fetters, Michael D
Mawocha, Samkeliso
Legocki, Laurie J
Barsan, William G
Lewis, Roger J
Berry, Donald A
Meurer, William J
The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project
title The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project
title_full The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project
title_fullStr The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project
title_full_unstemmed The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project
title_short The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project
title_sort life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the advancing regulatory science initiative of the national institutes of health and us food and drug administration: case studies from the adaptive designs accelerating promising treatments into trials project
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648086/
https://www.ncbi.nlm.nih.gov/pubmed/29085638
http://dx.doi.org/10.1177/2050312117736228
work_keys_str_mv AT guettermantimothyc thelifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatm
AT fettersmichaeld thelifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatm
AT mawochasamkeliso thelifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatm
AT legockilauriej thelifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatm
AT barsanwilliamg thelifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatm
AT lewisrogerj thelifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatm
AT berrydonalda thelifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatm
AT meurerwilliamj thelifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatm
AT guettermantimothyc lifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatment
AT fettersmichaeld lifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatment
AT mawochasamkeliso lifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatment
AT legockilauriej lifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatment
AT barsanwilliamg lifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatment
AT lewisrogerj lifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatment
AT berrydonalda lifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatment
AT meurerwilliamj lifecyclesofsixmulticenteradaptiveclinicaltrialsfocusedonneurologicalemergenciesdevelopedfortheadvancingregulatoryscienceinitiativeofthenationalinstitutesofhealthandusfoodanddrugadministrationcasestudiesfromtheadaptivedesignsacceleratingpromisingtreatment